Paul Marks

Q: What Schools Are Affiliated With Paul Marks

Paul Marks is affiliated with the following schools: Stanford University, Cornell University, University of Genoa, Johns Hopkins University, University of California, San Francisco, Columbia University, Harvard University, University of Arkansas

Paul Marks 's AcademicInfluence.com Rankings

Paul Marks

Medical

#375

World Rank

#527

Historical Rank

#159

USA Rank

Oncology

#18

World Rank

#19

Historical Rank

USA Rank

medical Degrees

Paul Marks

Philosophy

#3477

World Rank

#5612

Historical Rank

#1105

USA Rank

Logic

#1212

World Rank

#1903

Historical Rank

#377

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Paul Marks 's Degrees

Doctorate Medicine Johns Hopkins University

Why Is Paul Marks Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Paul Alan Marks was a medical doctor, researcher and administrator. He was a faculty member and president at Memorial Sloan Kettering Cancer Center. Background Marks was born in Mahanoy City, Pennsylvania, in 1926, to Robert Marks and Sarah Bohorad. Marks attended Columbia College and Columbia Medical School. After completing postdoctoral research at the United States National Institutes of Health and at the Institut Pasteur in France, he joined the faculty at Columbia University. Marks served as dean of the Medical Faculty at Columbia University from 1970 to 1973. He was president and chief executive officer at Memorial Sloan Kettering from 1980 until 1999. Marks died at his Manhattan home from pulmonary fibrosis and lung cancer on April 28, 2020, at the age of 93.

(See a Problem?)

Paul Marks 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Histone deacetylases and cancer: causes and therapies (2001) (1901)
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors (1999) (1580)
Histone deacetylase inhibitors: molecular mechanisms of action (2007) (1430)
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. (2000) (1208)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. (2000) (1150)
Histone Deacetylase Inhibitors: Overview and Perspectives (2007) (1106)
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug (2007) (1078)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. (2005) (898)
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. (1998) (860)
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease (2003) (853)
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003) (662)
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. (2000) (620)
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. (2004) (588)
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors (2004) (587)
Discovery and development of SAHA as an anticancer agent (2007) (577)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. (2004) (570)
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. (2005) (523)
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin (2002) (508)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. (2005) (505)
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. (1996) (433)
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. (2001) (355)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair (2010) (326)
A new group of potent inducers of differentiation in murine erythroleukemia cells. (1976) (317)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. (2003) (309)
Histone deacetylase inhibitors: discovery and development as anticancer agents (2005) (308)
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. (2001) (283)
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation (2008) (277)
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs (2010) (269)
Histone deacetylase inhibitors: from target to clinical trials (2002) (260)
Tumor promoters inhibit spontaneous and induced differentiation of murine erythroleukemia cells in culture. (1977) (235)
Cloning and characterization of a histone deacetylase, HDAC9 (2001) (235)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma (2007) (214)
Erythroleukemic differentiation. (1978) (214)
Differentiation of normal and neoplastic hematopoietic cells (1978) (213)
INHIBITION OF MAMMALIAN GLUCOSE-6-PHOSPHATE DEHYDROGENASE BY STEROIDS. (1960) (204)
Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. (1975) (204)
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor (2006) (201)
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. (1999) (200)
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents (2010) (192)
Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death (2012) (187)
Lipid synthesis in human leukocytes, platelets, and erythrocytes. (1960) (186)
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. (2010) (177)
Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. (1977) (173)
Induction of transformed cells to terminal differentiation and the modulation of gene expression. (1987) (165)
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. (2001) (160)
Erythrocyte glucose-6-phosphate dehydrogenase deficiency: evidence of differences between Negroes and Caucasians with respect to this genetically determined trait. (1959) (159)
Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy (2005) (153)
Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division. (1986) (151)
Modulation of Renal Disease in MRL/lpr Mice by Suberoylanilide Hydroxamic Acid1 (2004) (150)
SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease (2011) (147)
HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration (2013) (145)
PROTEIN SYNTHESIS IN ERYTHROID CELLS, I. RETICULOCYTE RIBOSOMES ACTIVE IN STIMULATING AMINO ACID INCORPORATION. (1962) (143)
EFFECT OF AGE ON THE ENZYME ACTIVITY IN ERYTHROCYTES. (1958) (140)
Inhibitors of histone deacetylase are potentially effective anticancer agents. (2001) (137)
Relationship between the age of human erythrocytes and their osmotic resistance: a basis for separating young and old erythrocytes. (1958) (134)
Globin Composition and Synthesis of Hemoglobins in Developing Fetal Mice Erythroid Cells (1967) (132)
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. (2001) (130)
Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. (2000) (127)
Chemically induced murine erythroleukemic differentiation. (1980) (127)
Clinical spectrum of hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency. (1966) (127)
Substances stimulating glucose catabolism by the oxidative reactions of the pentose phosphate pathway in human erythrocytes. (1961) (125)
In vitro synthesis of DNA components of human genes for globins. (1972) (125)
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. (2000) (122)
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. (1992) (122)
Erythroid cell development in fetal mice: ultrastructural characteristics and hemoglobin synthesis. (1967) (121)
The effect of erythropoietin on colonial growth of erythroid precursor cells in vitro. (1974) (121)
Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). (1999) (121)
Changes in DNA associated with induction of erythroid differentiation by dimethyl sulfoxide in murine erythroleukemia cells. (1978) (120)
An hereditary enzymatic defect in erythrocyte metabolism: glucose-6-phosphage dehydrogenase deficiency. (1958) (120)
Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. (2005) (120)
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells (1994) (117)
Development of a histone deacetylase 6 inhibitor and its biological effects (2013) (116)
The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test. (1957) (113)
Red cell glucose-6-phosphate and 6-phosphogluconic dehydrogenases and nucleoside phosphorylase. (1958) (111)
The composition and biosynthesis of lipids in human adipose tissues. (1961) (109)
Transient inhibition of initiation of S-phase associated with dimethyl sulfoxide induction of murine erythroleukemia cells to erythroid differentiation. (1977) (109)
Excess α Chain Synthesis Relative to β Chain Synthesis in Thalassaemia Major and Minor (1966) (108)
ALTERATIONS IN POLYRIBOSOMES DURING ERYTHROID CELL MATURATION (1964) (102)
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation (2007) (100)
Erythrocyte glucose 6-phosphate dehydrogenase of normal and mutant human subjects: properties of the purified enzymes. (1961) (100)
Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. (1994) (99)
Erythroid cell-development in fetal mice: synthetic capacity for different proteins. (1968) (97)
Protein Synthesis: Its Control in Erythropoiesis (1972) (96)
Induction of erythroid differentiation by dimethylsulfoxide in cells infected with Friend virus: relationship to the cell cycle. (1975) (95)
Histone deacetylase inhibitors selectively suppress expression of HDAC7 (2007) (94)
Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer (2005) (93)
Histone deacetylase inhibitors. (2004) (92)
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. (2001) (91)
Histone deacetylase inhibitors: development as cancer therapy. (2004) (87)
Erythropoietic differentiation in colonies of cells transformed by Friend virus. (1974) (87)
Erythroid cell differentiation: murine erythroleukemia cell variant with unique pattern of induction by polar compounds. (1976) (86)
Murine erythroleukemia cell differentiation: DNase I hypersensitivity and DNA methylation near the globin genes. (1982) (84)
Mechanisms of resistance to histone deacetylase inhibitors. (2012) (83)
Protein kinase C activity and hexamethylenebisacetamide-induced erythroleukemia cell differentiation. (1987) (83)
STUDIES ON THE MECHANISM OF AGING OF HUMAN RED BLOOD CELLS * (1958) (82)
DANON D: POLYRIBOSOMES AND PROTEIN SYNTHESIS DURING RETICULOCYTE MATURATION IN VITRO. (1963) (81)
Interleukin 3-dependent hematopoietic progenitor cell lines. (1983) (81)
Induction of erythroid differentiation of murine erythroleukemia cells by nicotinamide and related compounds. (1979) (80)
Decreased globin messenger RNA in thalassemia detected by molecular hybridization. (1973) (80)
Accumulation of α- and β-globin messenger RNAs in mouse erythroleukemia cells (1977) (77)
Histone deacetylases. (2003) (74)
Tetrose phosphate and the formation of sedoheptulose diphosphate. (1955) (73)
Inducers of erythroleukemic differentiation. Relationship of structure to activity among planar-polar compounds. (1978) (72)
Polyribosomes and control of protein synthesis: effects of sodium fluoride and temperature of reticulocytes. (1966) (71)
Inducer-mediated commitment of murine erythroleukemia cells to differentiation: a multistep process. (1982) (70)
Polyribosome dissociation and formation in intact reticulocytes with conservation of messenger ribonucleic acid. (1965) (69)
ERYTHROPOIETIN EFFECTS ON FETAL MOUSE ERYTHROID CELLS: I. Cell Population and Hemoglobin Synthesis (1971) (66)
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. (2003) (65)
Differential expression of protein kinase C isozymes and erythroleukemia cell differentiation. (1989) (64)
Increased efficiency of exogenous messenger RNA translation in a Krebs ascites cell lysate. (1972) (64)
Bassen-Kornzweig Syndrome: Deficiency of Serum β-Lipoprotein: A Neuromuscular Disorder Resembling Friedreich's Ataxia, Associated with Steatorrhea, Acanthocytosis, Retinitis Pigmentosa, and a Disorder of Lipid Metabolism (1963) (63)
Cloning of a D-type cyclin from murine erythroleukemia cells. (1992) (63)
Genetic Heterogeneity of Glucose-6-Phosphate Dehydrogenase Deficiency (1962) (63)
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. (2000) (62)
Thioredoxin in cancer--role of histone deacetylase inhibitors. (2006) (60)
Differential effects of chemical inducers on expression of beta globin genes in murine erythroleukemia cells. (1977) (60)
Gene expression in murine erythroleukemia cells. Transcriptional control and chromatin structure of the alpha 1-globin gene. (1984) (59)
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. (1998) (59)
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. (2002) (59)
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. (1988) (59)
Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation. (1989) (59)
Tumor promoter-mediated inhibition of cell differentiation: suppression of the expression of erythroid functions in murine erythroleukemia cells. (1979) (58)
Abnormal or absent β mRNA in β0 Ferrara and gene deletion in δβ thalassaemia (1976) (58)
Synthesis of embryonic hemoglobins during erythroid cell development in fetal mice. (1969) (58)
The Mechanism of the Anti-Tumor Activity of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA) (2004) (57)
Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. (1992) (57)
Induction of murine erythroleukemia differentiation by actinomycin D. (1978) (55)
PROTEIN SYNTHESIS IN ERYTHROID CELLS. II. POLYRIBOSOME FUNCTION IN INTACT RETICULOCYTES. (1964) (55)
Unstable ribonucleic acid in mammalian blood cells. (1962) (54)
The circulating splanchnic blood volume in dog and man. (1953) (54)
Potent cytodifferentiating agents related to hexamethylenebisacetamide. (1991) (54)
Changes in cyclic adenosine 3':5'-monophosphate levels during induction of differentiation in murine erythroleukemia cells. (1978) (54)
Protein p53 and inducer-mediated erythroleukemia cell commitment to terminal cell division. (1983) (52)
Tumor promoter-induced adhesion of the DS19 clone of murine erythroleukemia cells. (1979) (52)
Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1. (1993) (51)
Heterogeneity of murine erythroleukemia cells with respect to tumor promoter-mediated inhibition of cell differentiation. (1978) (51)
Differentiation of mammalian somatic cells: DNA and hemoglobin synthesis in fetal mouse yolk sac erythroid cells. (1969) (50)
Absolute rates of globin chain synthesis in thalassemia. (1968) (50)
Gene Action in Erythrocyte Deficiency of Glucose-6-phosphate Dehydrogenase: Tissue Enzyme-Levels (1959) (49)
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors (2011) (48)
Changes in splanchnic blood volume and splanchnic blood flow in dogs after haemorrhage. (1955) (48)
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells. (1990) (47)
Protein synthesis in a cell free human reticulocyte system: ribosome function in thalassemia. (1966) (47)
Replication of alpha and beta globin DNA sequences occurs during early S phase in murine erythroleukemia cells. (1981) (46)
Induced differentiation, the cell cycle, and the treatment of cancer. (1996) (46)
Changes in globin messenger RNA content during erythroid cell differentiation. (1975) (46)
Murine erythroleukemia cell differentiation: relationship of globin gene expression and of prolongation of G1 to inducer effects during G1/early S. (1979) (45)
SYNTHESIS OF RIBONUCLEIC ACID IN RABBIT BLOOD CELLS IN VIVO. (1964) (44)
Effect of dehydroepiandrosterone on glucose 6-phosphate dehydrogenase activity and reduced triphosphopyridine nucleotide formation in adrenal tissue. (1962) (44)
ERYTHROCYTE GLUCOSE-6-PHOSPHATE DEHYDROGENASE ACTIVITY AND X-CHROMOSOME POLYSOMY (1962) (41)
Tumor promoters enhance myeloid and erythroid colony formation by normal mouse hemopoietic cells. (1980) (41)
Relative numbers of human globin genes assayed with purified alpha and beta complementary human DNA. (1975) (41)
Globin messenger RNA activity in erythroid precursor cells and the effect of erythropoietin. (1972) (40)
STUDIES ON CARBOHYDRATE METABOLISM IN PATIENTS WITH NEOPLASTIC DISEASE. II. REPONSE TO INSULIN ADMINISTRATION (1959) (40)
Cell volume changes in relation to the cell cycle of differentiating erythroleukemic cells. (1978) (40)
Purification of erythropoietin-responsive cells by immune hemolysis. (1972) (39)
Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. (1996) (39)
Partial purification and properties of a ribonuclease from rabbit reticulocytes. (1968) (38)
Erythropoietin effects on fetal mouse erythroid cells. II. Nucleic acid synthesis and the erythropoietin-sensitive cell. (1972) (37)
Erythroleukemia cells: variants inducible for hemoglobin synthesis without commitment to terminal cell division. (1983) (37)
Pericardial effusion associated with myxedema. (1953) (36)
Ribosomes Active in Protein Synthesis in Human Reticulocytes : a Defect in Thalassæmia Major (1963) (36)
Differential modulation of protein kinase C isoforms in erythroleukemia during induced differentiation. (1993) (35)
Conservation of globin messenger RNA in rabbit reticulocyte monoribosomes after sodium fluoride treatment. (1972) (33)
Chapter 8 Development of Mammalian Erythroid Cells (1966) (33)
Effect of hemorrhage on estimated hepatic blood flow and renal blood flow in dogs. (1953) (33)
Transcriptional and post-transcriptional regulation of globin gene accumulation in murine erythroleukemia cells (1983) (32)
Synthesis of globin mRNA in relation to the cell cycle during induced murine erythroleukemia differentiation. (1978) (32)
Creation of a histone deacetylase 6 inhibitor and its biological effects (2015) (31)
Early stimulation of RNA synthesis by erythropoietin in cultures of erythroid precursor cells. (1973) (30)
Hemoglobins A and F: Formation in Thalassemia and Other Hemolytic Anemias (1964) (30)
Induced transcription of the mouse β-globintranscription unit in erythroleukemia cells (1984) (28)
Erythroid cell development in fetal mice: stabilization of the hemoglobin synthetic capacity. (1970) (28)
The biosynthesis of nucleic acid ribose and of glycogen glucose in the rat. (1957) (28)
Induction of Transformed Cells to Terminal Differentiation a (1987) (27)
A study of the mechanism by which triphosphopyridine nucleotide affects human erythrocyte glucose-6-phosphate dehydrogenase. (1962) (26)
DRUG‐INDUCED HEMOLYTIC ANEMIAS ASSOCIATED WITH GLUCOSE‐6‐PHOSPHATE DEHYDROGENASE DEFICIENCY: A GENETICALLY HETEROGENOUS TRAIT * (1965) (25)
Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells. (1989) (25)
A limited number of globin genes in human DNA. (1974) (24)
Distribution of radioactive carbon dioxide incorporated into rat liver glycogen. (1956) (24)
Curbing autophagy and histone deacetylases to kill cancer cells (2012) (23)
Polyribosomes Active in Reticulocyte Protein Synthesis (1963) (23)
A Newer Pathway Of Carbohydrate Metabolism; The Pentose Phosphate Pathway (1956) (21)
Induced differentiation of murine erythroleukemia cells: cellular and molecular mechanisms. (1984) (21)
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. (1997) (20)
Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential. (1989) (20)
Glucose-6-phosphate dehydrogenase thermostability in leukocytes of negroes and caucasians with erythrocyte deficiency of this enzyme☆ (1959) (20)
SIZE OF POLYRIBOSOMES IN INTACT RETICULOCYTES. (1964) (20)
Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation. (1988) (20)
Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application. (1988) (20)
Translation and stability of human globin mRNA in Xenopus oocytes. (1976) (19)
Excess alpha chain synthesis relative to beta chain synthesis in thalassaemia major and minor. (1966) (19)
RNA synthesized during differentiation of yolk sac erythroid cells. (1971) (19)
Inducer-mediated commitment of murine erythroleukemia cells to terminal cell division: the expression of commitment. (1984) (19)
HUMAN GLUCOSE‐6‐P DEHYDROGENASE: STUDIES ON THE RELATION BETWEEN ANTIGENICITY AND CATALYTIC ACTIVITY—THE ROLE OF TPN * (1963) (18)
A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis. (1992) (18)
Commitment to terminal differentiation and the cell cycle. (1982) (17)
Development of mammalian erythroid cells. (1966) (17)
Decreased β Globin mRNA Activity in Bone Marrow Cells in Homozygous and Heterozygous β Thalassaemia (1973) (17)
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. (2004) (16)
Hexamethylenebisacetamide-resistant murine erythroleukemia cells have altered patterns of inducer-mediated chromatin changes. (1983) (16)
Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells. (1992) (16)
Globin synthesis of intact cells and activity of isolated mRNA in -thalassaemia. (1973) (16)
Modulation of gene expression during terminal cell differentiation. (1985) (15)
Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation. (1991) (15)
Reticulocyte Protein Synthesis: Response of Ribosome Fractions to Polyuridylic Acid (1963) (15)
CONTROL MECHANISMS OF THE CONVERSION FROM SYNTHESIS OF EMBRYONIC TO ADULT HEMOGLOBIN * (1969) (15)
Hemodynamic effects of 1-hydrazinophthalazine in the dog, with special reference to circulating splanchnic blood volume. (1955) (15)
Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. (2009) (15)
At low dose, arginine vasotocin has vasopressor rather than vasodepressor effect in chickens. (1993) (14)
Pathways of glycogen formation in liver and skeletal muscle in fed and fasted rats. (1957) (14)
Blasts from the past. (2004) (14)
GLOBIN CHAIN SYNTHESIS IN THALASSEMIA * (1969) (14)
Oxytocin antagonist blocks the vasodepressor but not the vasopressor effect of neurohypophysial peptides in chickens (1994) (14)
Gene expression during terminal differentiation: dexamethasone suppression of inducer-mediated alpha 1- and beta maj-globin gene expression. (1985) (14)
Protein synthesis in erythroid cells. 3. Monoribosome and polyribosome function in the cell-free system. (1965) (14)
Production of Glucose by the Liver during Hyperglycæmia (1958) (14)
Hemoglobin synthesis in thalassemia. (1971) (13)
The hematocrit of the lesser circulation in man. (1956) (13)
Protein kinase C isozymes epsilon and alpha in murine erythroleukemia cells. (1992) (13)
Induced transcription of the mouse beta-globin transcription unit in erythroleukemia cells. Time-course of induction and of changes in chromatin structure. (1984) (13)
Variations in white blood cells following the oral administration of glucose to diabetics and nondiabetics. (1948) (13)
Metabolic effects of phenethyl alcohol on mammalian cells. (1967) (12)
[25] Glucose 6-phosphate dehydrogenase—Clinical aspects (1966) (12)
Stimulation of globin synthesis by RNA purified from reticulocyte supernatant fraction. (1968) (12)
Embryonic differentiation of sexual dimorphism in vasotocin and mesotocin levels in chickens (1992) (12)
Control of Hæmoglobin A and F Synthesis: Hæmoglobin Formation in Fœtal and Adult Erythroid Cells (1964) (12)
Fos is required for EGF stimulation of the gastrin promoter. (1996) (12)
Studies on carbohydrate metabolism in patients with neoplastic disease. II. Response to insulin administration. (1959) (11)
INDUCTION OF GLOBIN GENE EXPRESSION DURING ERYTHROID CELL DIFFERENTIATION * (1983) (11)
Clinical use of differentiating agents in cancer therapy. (1990) (11)
AN HEREDITARY ENZYMATIC DEFECT IN RED BLOOD CELLS: ITS RELATION TO CERTAIN DRUG‐INDUCED HEMOLYTIC ANEMIAS * (1958) (11)
Induction of murine erythroleukemia cells to differentiate: a model for the detection of new anti-tumor drugs. (1978) (11)
Induction of Murine Erythroleukemia Cells to Differentiate (1978) (11)
Erythroid differentiation and the cell cycle: some implications from murine foetal and erythroleukemic cells. (1976) (10)
Drug-induced hemolytic anemias and congenital galactosemia: examples of genetically determined defects in erythrocyte metabolism. (1959) (10)
Histone deacetylase inhibitors in the therapy of cancer: much to learn. (2010) (10)
Preparative polyacrylamide gel electrophoretic purification of human alpha- and beta-globin messenger RNAs. (1977) (10)
A method for evaluating the relation of glycogen to inorganic salt deposition in surviving cartilage slices in vitro. (1950) (9)
ERYTHROPOIETIN EFFECTS ON FETAL MOUSE ERYTHROID CELLS (1971) (9)
Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic. (1999) (9)
Thalassemia syndromes. Biochemical, genetic and clinical aspects. (1966) (9)
Genetics, cell differentiation, and cancer (1985) (8)
Glucose-6-phosphate dehydrogenase in mature erythrocytes. (1967) (8)
Induced erythroleukemia differentiation: cellular and molecular aspects. (1987) (8)
CONTROL OF PROTEIN SYNTHESIS IN RETICULOCYTES AND THE FORMATION OF HEMOGLOBINS A AND F IN THALAESSMIA SYNDROMES AND OTHER HEMOLYTIC ANEMIAS1 (1964) (8)
Accumulation of alpha- and beta-globin messenger RNAs in mouse erythroleukemia cells. (1977) (8)
Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators. (1996) (8)
Modulation of gene expression during terminal cell differentiation: murine erythroleukemia. (1984) (8)
Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation. (1999) (8)
REGULATION OF GLOBIN SYNTHESIS IN THE THALASSEMIAS * (1974) (8)
Protein Synthesis in Cell-free Systems from Reticulocytes of Thalassaemic Patients (1969) (7)
Genetic control of hemoglobin synthesis and the thalassemia syndromes. (1969) (7)
Enzymes of the pentose phosphate pathway. (1961) (7)
CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy (2015) (7)
Cold-induced accumulation of ribosomal subunits from human reticulocytes. (1971) (7)
Hemoglobin Synthesis in Human Reticulocytes: A Defect in Globin Formation in Thalassemia Major * (1964) (7)
[27] 6-Phosphogluconate dehydrogenase—Clinical aspects (1966) (7)
Control of gene expression during erythroid cell differentiation. (1974) (6)
Chapter 2 – Erythropoiesis (1974) (6)
Inhibition of induced murine erythroleukemia cell differentiation by tumor promoters: relation to the cell cycle. (1980) (6)
Stability of alpha and beta globin messenger RNA during induced differentiation of mouse erythroleukemia cells (1979) (6)
Erythroid cell differentiation (1978) (6)
8 – Erythroleukemia Cells (1992) (6)
Fetal erythropoiesis: erythropoietin effects on cultured cells. (1969) (6)
DECREASED GLOBIN MESSENGER RNA IN THALASSEMIA BY HYBRIDIZATION AND BIOLOGIC ACTIVITY ASSAYS * (1974) (6)
Molecular pathology of thalassemia syndromes. (1971) (5)
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells 1 (2001) (5)
Differentiating agents in cancer therapy. (1991) (5)
Hemoglobin synthesis and differentiation of erythroid cells. (1968) (5)
Effects of inhibitors on calcium deposition in cartilage in vitro. (1953) (5)
DNA polymerase activities during induced differentiation in murine erythroleukemia cells. (1981) (5)
Genetically determined susceptibility to cancer. (1981) (4)
Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC. (1989) (4)
Glucose-6-P dehydrogenase stability, activation, and inactivation. (1961) (4)
Isolation and in vitro differentiation of human erythroid precursor cells. (1976) (4)
Epigenetic targeted anti-cancer drugs: an unfolding story. (2011) (4)
Hemolytic Anemia Associated with Liver Disease (1963) (4)
Biosynthesis of Liver and Tumor RNA Ribose in the Tumor-Bearing Rat (1957) (4)
Relative Numbers of Human Globin Genes Assayed with Purified a and , Complementary Human DNA (4)
Balanced accumulation of α‐ and β‐globin mRNA in differentiating fetal mouse erythroid cells (1978) (4)
Factors influencing deposition of calcium and strontium in cartilage in vitro. (1953) (4)
Protein synthesis in human reticulocytes induced by therapy of megaloblastic anemia. (1967) (4)
Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells (1990) (3)
Mitochondrial Pathogenesis (2004) (3)
CONTROL OF HAEMOGLOBIN A AND F SYNTHESIS: HAEMOGLOBIN FORMATION IN FOETAL AND ADULT ERYTHROID CELLS. (1964) (3)
Polyribosomes and control of hemoglobin synthesis. (1966) (3)
The effect of L-norepinephrine on urine composition and acid-base equilibrium in man. (1957) (3)
Depression of lymphocyte count after orally administered glucose. (1948) (3)
HISTONE DEACETYLASE INHIBITORS: NOVEL TARGETED ANTI-CANCER AGENTS (2005) (3)
Regulation of differentiation of erythroid cells. (1972) (3)
Regulation of differentiation in transformed erythroid cells. (1978) (3)
The thalassemia syndromes and the intracellular regulation of globin synthesis. (1973) (3)
DRUG-INDUCED HEMOYTIC ANEMIAS ASSOCIATED WITH GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY: AGENETICALLY HETEROGENOUS TRAIT. (1965) (2)
Decreased beta globin mRNA activity in bone marrow cells in homozygous and heterozygous beta thalassaemia. (1973) (2)
The American Society for Clinical Investigation--the first 100 years. (2008) (2)
Regulation of globin gene expression during induced erythroid cell differentiation. (1983) (2)
Regulation of murine ?-, ?major-, and ?minor-globin gene expression (1988) (2)
Cancer research in the People's Republic of China and the United States of America: epidemiology, causation and new approaches to therapy. (1981) (2)
Differentiation and the Role of Differentiation Inducers in Cancer Treatment (2002) (2)
Health systems research in the mainstream of academic medicine. (1972) (2)
HDAC inhibitors: much to learn about effective therapy. (2010) (2)
Differentiating agents for transformed cells. (1993) (2)
Effects of murine leukemia virus infection on self-renewal of pluripotential hematopoietic stem cells in vitro and in vivo. Abstr. (1982) (1)
Differentiating agents in cancer therapy. (1991) (1)
Nutrition and the cancer problem. (1977) (1)
proteins, including HDAC1 (2004) (1)
Histone Deacetylase Inhibitors: Development as Anticancer Agents (2008) (1)
Relationship between globin mRNA accumulation and commitment to terminal cell differentiation in inducer sensitive and resistant erythroleukemia variants. (1990) (1)
Commitment, DNA synthesis and gene expression in erythroleukemia cells. (1982) (1)
Advances in Brief The Histone Deacetylase Inhibitor , CBHA , Inhibits Growth of Human Neuroblastoma Xenografts in Vivo , Alone and Synergistically with All-Trans Retinoic Acid 1 (2001) (1)
Commitment: a multi-step process during induced MELC differentiation. (1982) (1)
Mitochondrial functional changes during hepatic hyperplasia and azo dye carcinogenesis. (1976) (1)
Abnormal or absent beta mRNA in betao Ferrara and gene deletion in delta beta thalassaemia. (1976) (1)
Regulation of differentiation in normal and transformed erythroid cells (2007) (1)
The regulation of hemoglobin synthesis in the fetal mouse. (1971) (1)
Molecular Oncology: Histone deacetylase inhibitors (2013) (1)
The preliminary study on HMBA-induced differentiation of the drug-pretreated murine erythroleukemia cells (1989) (1)
COMMENTS ON FEDERAL POLICY IN BIOMEDICAL RESEARCH (1980) (1)
The Emperor of All Maladies (2010, Scribner) By Siddhartha Mukherjee. (2011) (1)
Balanced accumulation of alpha- and beta-globin mRNA in differentiating fetal mouse erythroid cells. (1978) (1)
Changes in gene expression during hexamethylene bisacetamide induced erythroleukemia differentiation. (1987) (1)
Changes in p 34 cdc 2 Kinase Activity and Cyclin A during Induced Differentiation of Murine Erythroleukemia Cells ’ (2005) (1)
Syndrome: Deficiency of Serum \g=b\-Lipoprotein (2016) (0)
Changes in DMA Associated with Induction of Erythroid Differentiation by Dimethyl Sulfoxide in Murine Erythroleukemia Cells 1 (2006) (0)
A permanent mouse bone marrow stromal cell line demonstrates corticosteroid-dependent adipocyte differentiation and support of engrafted hematopoietic stem cells in vitro. Abstr. (1981) (0)
Murine Erythroleukemia: Cell Surface and Cell Cycle-Related Events in Induced Differentiation (1978) (0)
Protein kinase C isozymes e and a in murine erythroleukemia cells (2004) (0)
Hemolytic Syndromes Associated with Glucose-6 Phosphate Dehydrogenase Deficiency. (1966) (0)
Response : Fetal Liver Erythropoiesis and Yolk Sac Cells (1972) (0)
Defining the apoptotic pathways underlying HDAC inhibitor-mediated tumor therapy in vivo (2008) (0)
Abstract LB-55: Histone deacetylase inhibitor causes DNA damage and apoptosis by downregulation of repair enzymes in cancer but not normal cells: Basis of resistance of normal cells to HDACi (2010) (0)
malignant B cells Molecular sequelae of histone deacetylase inhibition in human (2013) (0)
How does the brain function during starvation ? 1972 – 1977 (2004) (0)
[The molecular pathogenesis of the thalassemia syndromes (author's transl)]. (1975) (0)
Restriction endonuclease sensitivity of DNA containing globin genes in different murine erythroleukemia cell lines. (1981) (0)
On the Cancer Frontier: One Man, One Disease, and a Medical Revolution (2014) (0)
Role of pro- and anti-apoptotic proteins in prostate cancer cells sensitive and resistant to histone deacetylase inhibitor induced cell death (2006) (0)
Regulation of murine alpha-, beta major-, and beta minor-globin gene expression. (1988) (0)
Stability of alpha and beta globin messenger RNA during induced differentiation of mouse erythroleukemia cells. (1979) (0)
Releasing effect of thymidine on G1 phase arrest of erythroleukemia cells caused by FUDR and HMBA. (1984) (0)
76. Membrane alterations associated with hexamethylene bisacetamide (HMBA) induced differentiation of murine erythroleukemia cells (MELC) (1992) (0)
A man who has made his Marks on science. (2006) (0)
Distinguished address: Genetic predisposition to cancer. (1981) (0)
Abstract A206: Chk1 protects normal cells from HDAC inhibitor-induced cell death. (2011) (0)
Some lmplications of the Advances in Human Genome Research (1997) (0)
ON DISSOCIATION AND RECOMBINATION OF H UMA N ADULT HEMOGLOBINS (0)
162. Phase II clinical trial with hexamethylene bisacetamide (HMBA) in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) (1992) (0)
Anti-bug software foretells cell fate (2014) (0)
Approaches to more effective induction of cytodifferentiation of transformed cells and potential for cancer treatment. (1990) (0)
Induced Differentiation of Transformed Cells by Polar Compounds: From Molecular Studies to Clinical Trials (1989) (0)
Federal policy in biomedical research: the report of the President's Biomedical Research Panel. (1976) (0)
Biochemical aspects of the pathogenesis of the thalassemia syndromes. (1973) (0)
Letter from Paul A. Marks to Joshua Lederberg (1958) (0)
Letter from Paul A. Marks, Memorial Sloan-Kettering Cancer Center to Joshua Lederberg (1987) (0)
119. Hexamethylene bisacetamide (HMBA)-induced reduction in diacylglycerol levels is associated with differentiation of murine erythroleukemia cells (1992) (0)
The impact of recent progress in molecular biology on biomedical academic institutions. (1982) (0)
based on a HDAC 6 for cancer treatment methods (2010) (0)
Academic health centers and the federal government: a partnership in research, education, and patient care. (1981) (0)
The erythropoietin-responsive cell. Abstr. (1971) (0)
Abstract LB-308: Development of histone deacetylase 6 inhibitors: Effects of HDAC6 inhibitors in normal and cancer cells. (2013) (0)
Phase I Clinical Trial of Histone Deacetylase Inhibitor : Suberoylanilide Hydroxamic Acid Administered Intravenously 1 (2003) (0)
Replication of a and .8 globin DNA sequences occurs during early S phase in murine erythroleukemia cells (0)
Carbohydrate metabolism. Metabolic interrelations and control. (1960) (0)
Correction (1992) (0)
Perspectivesin CancerResearch Induction of Transformed Cells to Terminal Differentiation and the Modulation of Gene Expression1 (2006) (0)
Normal and neoplastic hematopoiesis : proceedings of the UCLA symposium held at Steamboat Springs, Colorado, March 27-April 1, 1983 (1983) (0)
Globin messenger RNA content during erythroid cell differentiation. (1974) (0)
Erythroid Cell Maturation and the Control of Hemoglobin A and F Formation. (1965) (0)
EFFECT OF Ar ’ rnsmlA TO ERYTHROPOIETIN ON THE IN Vrruo FE 59 INCORPORATION BY RABBIT BONE MARROW CELLS (2005) (0)
Gene expression during terminal differentiation: Dexamethasone suppression of inducer-mediated cal- and pma-globin gene expression division/chromatin/hexamethylenebisacetamlde/ gene transcription i/erythroleukemia) (2003) (0)
PATHWAYSOF GLYCOGENFORMATION IN LIVER AND SKELETAL MUSCLE IN FED AND FASTED RATS (2013) (0)
Changes in rna synthesized as yolk sac erythroid cell (ysec) differentiate. Abstr. (1970) (0)
New efficient, terminal differentiation-inducing agents, and methods for their use (1994) (0)
Role of differentiation induction in tumor suppression. (1990) (0)
[Biochemical aspects of the aging of the erythrocyte and of hemolytic anemia of medicamentous origin]. (1961) (0)
Abstract LB-33: Selective inhibition of Histone Deacetylase 6 enhances transformed cell sensitivity to anti-cancer agents (2010) (0)
Differentiation of erythroid cells. (1971) (0)
Cardiovascular effects of angiotensin-II in chickens. (1995) (0)
New potent inducers of terminal differentiation and methods for their use (1990) (0)
Mice by Suberoylanilide Hydroxamic Acid lpr Modulation of Renal Disease in MRL / Marks and (2004) (0)
Reminiscence and perspective (1987) (0)
Red cell enzymes glucose-6-phosphate dehydrogenase deficiency. (1968) (0)
Expression of erythroid differentiation and terminal cell division in induced Friend leukemia cells. (1981) (0)

This paper list is powered by the following services:

Other Resources About Paul Marks

en.wikipedia.org

What Schools Are Affiliated With Paul Marks ?

Paul Marks is affiliated with the following schools:

Paul Marks 's Academic­Influence.com Rankings

Paul Marks 's Degrees

Why Is Paul Marks Influential?

Paul Marks 's Published Works

Published Works

Other Resources About Paul Marks

What Schools Are Affiliated With Paul Marks ?

Paul Marks 's AcademicInfluence.com Rankings